LY2828360

LY2828360 is a cannabinoid (CB) receptor 2 agonist (Ki = 40.3 nM). It selectively activates CB2 over CB1 in a GTPgammaS binding assay (EC50s = 20.1 and >100,000 nM, respectively). It reduces differences in hind paw weight bearing between monoiodoacetic acid- and saline-injected knees in a rat model of knee joint-related chronic pain induced by monoiodoacetic acid (MIA) when administered at doses greater than or equal to 0.1 mg/kg. LY2828360 dose-dependently reduces mechanical and cold allodynia induced by paclitaxel (Cay-10461) in mice and prevents development of morphine tolerance when administered at dose of 3 mg/kg per day for 12 days. It also reduces paclitaxel-induced allodynia in morphine-tolerant mice.Formal Name: 8-(2-chlorophenyl)-2-methyl-6-(4-methyl-1-piperazinyl)-9-(tetrahydro-2H-pyran-4-yl)-9H-purine. CAS Number: 1231220-79-3. Molecular Formula: C22H27ClN6O. Formula Weight: 426.9. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: Chloroform: 30 mg/ml. lambdamax: 219, 284 nm. SMILES: CN1CCN(C2=C(N=C(C3=C(Cl)C=CC=C3)N4C5CCOCC5)C4=NC(C)=N2)CC1. InChi Code: InChI=1S/C22H27ClN6O/c1-15-24-21(28-11-9-27(2)10-12-28)19-22(25-15)29(16-7-13-30-14-8-16)20(26-19)17-5-3-4-6-18(17)23/h3-6,16H,7-14H2,1-2H3. InChi Key: UCMNDPDJRSEZPL-UHFFFAOYSA-N.